Biodexa Pharmaceuticals (BDRX) has released an update.
Biodexa Pharmaceuticals has successfully regained compliance with Nasdaq’s $1.00 minimum bid price requirement, ensuring its continued listing on the stock exchange. The company, known for developing treatments for diseases with unmet medical needs, received an exception to meet this requirement and remains under a discretionary panel monitor until February 2025. This development may boost investor confidence in Biodexa as it advances its innovative drug pipeline, including products targeting cancer and diabetes.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
